Search

Displaying results 6111 - 6120 of 10000 in total
  1. Drug

    Seproxetine

    go.drugbank.com/drugs/DB06731
    Experimental

    It is an active metabolite of fluoxetine. Seproxetine was being investigated by Eli Lilly as an antidepressant but development was never completed and the drug was never marketed.

  2. Drug

    NPS-2143

    go.drugbank.com/drugs/DB05695
    Experimental

  3. Drug

    Dextrorphan

    go.drugbank.com/drugs/DB14682
    Experimental

    Synonyms: (+)-N-methylmorphinan-3-ol, d-3-hydroxy-N-methylmorphinanCategories: Compounds used in a research, industrial, or household setting
  4. Drug

    Cepharanthine

    go.drugbank.com/drugs/DB16824
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Ferrous succinate

    go.drugbank.com/drugs/DB14489
    ApprovedInvestigational

  6. Drug

    DAS-431 IV

    go.drugbank.com/drugs/DB05432
    Experimental

    DAS-431 IV is a dopamine D1 receptor agonist developed by DrugAbuse Sciences for the treatment of Addictions, Schizophrenia, Schizoaffective Disorders, Dementia, Parkinson's Disease, Strokes etc.

  7. Drug

    G305

    go.drugbank.com/drugs/DB17292
    Investigational

    G305 is a [recombinant NY-ESO-1 protein] plus glucopyranosyl lipid A (GLA) in a stable emulsion (SE). G305 is an active component of CMB305 along with [LV305].[L47346]

  8. Drug

    Etamivan

    go.drugbank.com/drugs/DB08989
    ApprovedWithdrawn

    It is no longer used in the United States.

  9. Drug

    Etazolate

    go.drugbank.com/drugs/DB05881
    Investigational

    EHT 0202 is developed to treat neurodegenerative disorders by ExonHit Therapeutics.

  10. Drug

    Brasofensine

    go.drugbank.com/drugs/DB04857
    Experimental

    In November 2001, NeuroSearch confirmed that the drug's development was discontinued in favor of NS 2230. … Brasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K.